Comparative effectiveness of an individualized model of hemodialysis vs conventional hemodialysis: a study protocol for a multicenter randomized controlled trial (the TwoPlus trial)
Mariana Murea,Jochen G Raimann,Jasmin Divers,Harvey Maute,Cassandra Kovach,Emaad M Abdel-Rahman,Alaa S Awad,Jennifer E Flythe,Samir C Gautam,Vandana D Niyyar,Glenda V Roberts,Nichole M Jefferson,Islam Shahidul,Ucheoma Nwaozuru,Kristie L Foley,Erica J Trembath,Merlo L Rosales,Alison J Fletcher,Sheikh I Hiba,Anne Huml,Daphne H Knicely,Irtiza Hasan,Bhaktidevi Makadia,Raman Gaurav,Janice Lea,Paul T Conway,John T Daugirdas,Peter Kotanko,Two Plus Research Consortium,Denisse A Funes,Jessica Guillaume,Victoria Shoyelu,Katherine Vergara,Lyn B Lyman,Fatima Salmi,Erika Adams,Jessica Farrell,Nancy Ginsberg,Christa Howard,Suzanne Shabdue,Shawanna Jackson,Seth Johnson,Randall D Blackie,Sheetal Chaudhuri,Priya Desai,Kristy Hamilton,Igor Shumilin,Diana Clynes,Valerie Gonzalez,Erin Kahle,Marie Mitchell,Jennifer Rate,Brindusa Burciu,Lilliana Serrano,Alexandra Peluso,Valeria G Bittencourt,Zohreh Forghani,Elnaz R Ghalechi,Allison Green,Marina Markovic,Debra Martin,Caroline Poulton,Simran Singh,Katlyn Stiles,Ashleigh Trapuzzano,Joni Baker,Susan Trynosky
DOI: https://doi.org/10.1186/s13063-024-08281-9
IF: 2.728
2024-06-28
Trials
Abstract:Background: Most patients starting chronic in-center hemodialysis (HD) receive conventional hemodialysis (CHD) with three sessions per week targeting specific biochemical clearance. Observational studies suggest that patients with residual kidney function can safely be treated with incremental prescriptions of HD, starting with less frequent sessions and later adjusting to thrice-weekly HD. This trial aims to show objectively that clinically matched incremental HD (CMIHD) is non-inferior to CHD in eligible patients. Methods: An unblinded, parallel-group, randomized controlled trial will be conducted across diverse healthcare systems and dialysis organizations in the USA. Adult patients initiating chronic hemodialysis (HD) at participating centers will be screened. Eligibility criteria include receipt of fewer than 18 treatments of HD and residual kidney function defined as kidney urea clearance ≥3.5 mL/min/1.73 m2 and urine output ≥500 mL/24 h. The 1:1 randomization, stratified by site and dialysis vascular access type, assigns patients to either CMIHD (intervention group) or CHD (control group). The CMIHD group will be treated with twice-weekly HD and adjuvant pharmacologic therapy (i.e., oral loop diuretics, sodium bicarbonate, and potassium binders). The CHD group will receive thrice-weekly HD according to usual care. Throughout the study, patients undergo timed urine collection and fill out questionnaires. CMIHD will progress to thrice-weekly HD based on clinical manifestations or changes in residual kidney function. Caregivers of enrolled patients are invited to complete semi-annual questionnaires. The primary outcome is a composite of patients' all-cause death, hospitalizations, or emergency department visits at 2 years. Secondary outcomes include patient- and caregiver-reported outcomes. We aim to enroll 350 patients, which provides ≥85% power to detect an incidence rate ratio (IRR) of 0.9 between CMIHD and CHD with an IRR non-inferiority of 1.20 (α = 0.025, one-tailed test, 20% dropout rate, average of 2.06 years of HD per patient participant), and 150 caregiver participants (of enrolled patients). Discussion: Our proposal challenges the status quo of HD care delivery. Our overarching hypothesis posits that CMIHD is non-inferior to CHD. If successful, the results will positively impact one of the highest-burdened patient populations and their caregivers. Trial registration: Clinicaltrials.gov NCT05828823. Registered on 25 April 2023.